|
 |
|
|
|
|
|
|
|
 |
|
 |
|
|
|
Investments -
Life Sciences
|
 |
|
Committed to Quality of Life
With an aging world population, a rising interest in personal health management, increased amounts of disposable income, and the access to up-to-date information afforded by the Internet – life extension and quality of life improvement are primary motivators in the Life Sciences market, and the driving force behind GlenRock's Life Sciences investment strategy.
Investing in Tomorrow's Pioneers
With the right combination of a highly-developed medical community, world-class scientific resources, and excellent technological capabilities, Israel has produced numerous commercial Life Sciences success stories. GlenRock identifies and invests in cutting-edge Israeli Life Sciences technology at all stages of commercialization – from ideas on paper to viable companies breaking new ground in the fields of medical devices and biotechnology.
GlenRock's well-rounded Life Sciences portfolio includes:
|
 |
|
 |
 |
Kamada (TASE:KMDA) is a biopharmaceutical company engaged in development, production and marketing of specialty plasma therapeutics, specific and general immune globulins and other prescribed medicines using sophisticated chromatographic purification technology.
Kamada is producing more than 10 different pharmaceuticals primarily for critical care situations that arise in emergency rooms, operating theaters and intensive care units.
The products are licensed and marketed in the local market and in 15 other countries across the globe.
Latest News: On July 1st, 2010, the company received an FDA approval for its lead product the Glassia - a new liquid, ready- to-use treatment for Alpha-1 Antitrypsin Deficiency and entered into a strategic agreement for its distribution and manufacturing with Baxter. In addition the company received an EMEA clearance to enter phase 2/3 in its inhaled product. The Aerosolized AAT was also granted a new orphan drug designation for the treatment of Bronchiectasis for which the company completed phase 2 trial. Furthermore, the company reported successful completion of phase 2 trial in Cystic Fibrosis patients with its Aerosolized AAT. The company also received an FDA approval to enter into a fast track Phase III in the KamRab product - An anti-rabies immune globulin. During 2011 Kamada obtained an FDA orphan drug status for its intravenous AAT treatment for type 1 diabetes.
http://www.kamada.com
|
|
|
|
|
 |
|
Evogene (TASE:EVGN) is an agro-biotechnology company specializing in the development of superior crops through genome remodeling. Evogene's solutions are based on the tight integration of patented technologies and expertise in computational genomics, functional genomics and advanced high throughput plant breeding. Evogene's core technology platform mimics and accelerates evolutionary processes and can address concerns associated with transgenic plants.
Latest News: The company announced a strategic collaboration with Monsanto (NYSE: MON) one of the worldwide leading seed companies. Additional collaborations were established with Bayer CropScience, DuPont, Biogemma and other leading companies. The company established a cooperation with NASA in the field of Biofuel and during 2012 the company established Fully Owned Subsidiary Evofuel Ltd. for developing Advanced Feedstock for Biofuel.
http://www.evogene.com
|
|
|
|
|
 |
|
Rosetta Genomics (NasdaqGM: ROSG) is an integrative genomics company which has recently discovered a large number of novel genes related to many major diseases, using a radically novel bioinformatic approach. Rosetta Genomics licenses use of the company's numerous patent-pending disease-related genes to drug and diagnostic developers and manufacturers, who develop next-generation gene-based therapeutics and diagnostics based upon these genes.
Latest News: During 2007 the company completed a successful IPO on NASDAQ The company entered into an exclusive U.S. During 2011 the company announced the IPO of Majority-Owned Subsidiary Rosetta Green on the Tel Aviv Stock Exchange (TASE: RSTG) aimed to advance microRNA Technology in Cleantech, and later on sold its position in the company for an upfront payment and potential future payments.
http://www.rosettagenomics.com
|
|
|
|
|
 |
|
Vascular Biogenics (VBL) is a biopharmaceutical company dedicated to the development of innovative therapies targeting the vascular wall. Based on more than 10 years of academic research in one of the leading medical centers in Israel, VBL's products introduce novel approaches to the fight against cancer and cardiovascular diseases. VBL's vision is to develop safe and simple solutions based on understanding and mimicking natural processes occurring within the vascular wall.
Latest News: The company's compound for the treatment of patients with psoriasis is currently in Phase 2. The company is also entered Phase 2 clinical development with its lead oncology drug candidate, which successfully completed a Phase 1/2 trial in patients with cancer.
http://www.vbl.co.il
|
|
|
|
|
 |
|
LifeBond is a medical device company engaged in the development of active hemostatic solutions to minimize fatalities and damage from trauma wounds and surgical injuries. LifeBond will further develop its core technology into a range of products with the goal to establish a leading position in emerging bio-surgical market niches.
Latest News: During Q1 2012 a clinical trial is to be launched.
|
|
|
|
|
 |
|
BrainsGate develops a novel technology for modulation of cerebro-vascular properties through neuro-stimulation of the spheno-palatine ganglion. Affected properties are central to many CNS disorders - blood vessel permeability and blood flow. Currently targeted applications include treatment of ischemic stroke and drug delivery to the CNS through modifying the permeability of the blood brain barrier. The Company has initiated clinical trials, delivering a chemotherapeutic agent to primary brain tumor patients.
Latest News: The company is conducting clinical trials in India, Germany, Israel and Hungary.
http://www.brainsgate.com/
|
|
|
|
|
 |
|
Valtech Cardio is developing Percutaneous Annuloplasty ring valve repair for the treatment of Mitral Valve Regurgitation. Using a simple catheterization process for implementing the device which treats Mitral Valve Regurgitation, Valtech's treatment will be an alternative to the invasive open heart procedures that are currently in use today.
Latest News: During 2011 the company successfully completed clinical studies of its generation 1 products and continues the development of it novel line of products. NGN Biomed joined as a lead investor.
http://www.valtechcardio.com
|
|
|
|
|
 |
|
NESS utilized the technology of surface neuromuscular electrical stimulation to develop solutions for activating paralyzed muscles. Its first product is the Handmaster - a non-invasive system for paralyzed hands. NESS is developing innovative rehabilitation products that focus on altered movement or paralysis due to disorders and trauma of the central nervous system, or due to orthopedic disorders. The NESS systems are designed for home use and provide the potential for both therapeutic benefits and enhanced function by means of surface neuromuscular electrical stimulation.
Latest News: During 2007 the company was sold to Bioness.
http://www.nessltd.com/
|
|
|
|
|
 |
|
Bioness offers award-winning medical devices designed to benefit people with stroke, Multiple Sclerosis, traumatic brain injury, Cerebral Palsy, and spinal cord injury. These products use electrical stimulation to help people regain mobility and independence, to improve quality of life and productivity.
Latest News: During 2011 the company started to distribute new products for neurologically impaired patients and received clearance from FDA and CE Mark Approval by the European Union for its Wireless Hand Rehabilitation System.
http://www.bionessinc.com/
|
|
|
|
|
 |
|
Roei Medical Technologies develops innovative technology (FDA and CE approved) that improves the accuracy, efficacy, and safety of endoscopic urological procedures. The Roei resectoscope uses a unique scooping motion to provide surgeons the flexibility of approaching a tumor or tissue from a different angle, which translates the axial maneuver at the handgrip into a rotational side-to-side, bidirectional movement at the distal cutting edge.
Latest News: The company's products were approved for marketing by the FDA and the CE.
http://www.roeimedical.com/
|
|
|
|
|
 |
|
Visionsense is positioning itself as a high-end technology company, aiming to drive the Minimally Invasive Surgery ("MIS") visualization market from 2-Dimensional optics to "smart" 3-Dimensional sensors.
Latest News: During 2011 the company, the only 3D MIS player, saw continued adoption of 3D visualization in minimally invasive surgery.
http://www.visionsense.com
|
|
|
|
|
Yossi Gross
Bio Sciences |
|
Yossi Gross is a serial entrepreneur in the field of advanced technologies for medical devices.
Yossi has established 15 companies thus far, in most of which GlenRock has invested, including:
- BioControl - New generation of active implantable devices affecting the behavior of muscles and nerves of the autonomic nervous system. The company sold its urology business for $90M to American Medical Systems.
- BrainsGate - Unique neuro-stimulation treatment for stroke.
- DuoCure - Innovative intraluminal minimally invasive implantable device for treatment of obesity.
- Beta-Stim - Minimally invasive implantable neuro-stimulator to treat obesity and type II diabetic patients.
|
|
|
|
 |
|
Rainbow Medical -
A private investment company founded by the serial entrepreneur Yossi Gross, GlenRock Israel and managed by Efi Cohen-Arazi, which aims to seed and grow companies, mostly invented by the serial entrepreneur Yossi Gross, that develop breakthrough medical device-based therapeutic platforms addressing significant unmet market need and leads them to becoming high value companies. Rainbow Medical is committed to generating significant returns from its portfolio of cutting edge medical device technologies in a diverse range of medical fields. Collaboration was established with OXO Capital, a US based team of seasoned medical device professionals, founded and led by Larry Best, with a track record of successful execution in the medical device space. The OXO team provides access to an extensive network of industry relationships and contacts, experience based strategic guidance and insight as well as a geographic US presence. Among Rainbow's investors are major players in the industry as Medtronic.
Latest News: Maxillent completed clinical studies including follow up; received a European CE Mark. GluSense completed a successful European clinical study. Enopace, Slender, Fibro Control, Vascular Dynamics, Bluewind, Affix and Pharmalight initiated First in Man clinical studies throughout 2011.
http://www.rainbowmedical.co.il/
|
|
|
 |
|
 |
|
|
|
